The Cooper Companies, Inc. (COO) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of October 3, 2026. The Healthcare name (Medical Instruments & Supplies) last closed at $56.91. The rating moved from Neutral to Overbought on September 29, 2026.

• Public ratingOverbought (as of October 3, 2026)
• Last close$56.91
• Last changeMoved from Neutral to Overbought on September 29, 2026
• SectorHealthcare
• IndustryMedical Instruments & Supplies

See all overbought Healthcare stocks →

AI analysis

The Cooper Companies, Inc. (COO) combines a high‑share contact‑lens franchise with a growing women's‑health and surgical business, producing steady recurring revenue and solid free cash flow. Near-term trading will be influenced by risk‑off market tone and healthcare/device sentiment, while longer visibility depends on elective procedure trends, product cycle execution and margin maintenance. Operational strengths include product diversification, global reach and R&D pipeline; key vulnerabilities are competitive pressure, supply chain/regulatory shocks and reimbursement/policy shifts. Absent a clear sector catalyst or outsized M&A, expect confined upside in the coming weeks with gradual appreciation if execution and procedure demand remain stable.

Key factors

• Market leadership in soft contact lenses via CooperVision with diversified global footprint and recurring consumable revenue
• Business diversification with CooperSurgical exposure to women's health, fertility and surgical products reduces single-market concentration
• Stable cash flow generation and historically solid margins for a medical device/consumables company supporting operational resilience
• Post‑pandemic elective procedure recovery provides demand tailwinds for surgical and fertility segments
• Prudent balance-sheet position enabling continued investment in R&D, targeted M&A or share repurchases (supports optionality)
• Limited immediate macro sensitivity relative to pure discretionary names, but valuation depends on durable growth visibility

Risks

• Near-term market risk and risk‑off sentiment compressing device/healthcare multiples and delaying re‑rating
• Elective-procedure or fertility demand volatility tied to macro, consumer confidence or reimbursement changes
• Supply-chain disruptions or component shortages that could pressure fulfillment and margins
• Intense competition from large incumbents (e.g., Alcon, Bausch + Lomb, Johnson & Johnson) on product development and pricing
• Regulatory, quality or recall risk in manufacturing sites that could cause reputational and financial hits
• Currency and international exposure given significant non‑U.S. sales
• Potential downward pricing pressure from payers or policy actions that affect procedure reimbursement or product pricing

Latest MarketMoodz coverage

• Lululemon and Micron Lead Premarket Movers on Earnings, Guidance2026-06-05

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.